Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of August 2021, with a report date of August 23, 2021. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Price: $41.8100 per ADS.
- Transaction Volume: Total of 2,582.642 ADSs acquired across three transactions.
- Exchange: New York Stock Exchange (XNYS).
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine acquisitions of ADSs by executives via dividend reinvestment plans.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of specific share transactions executed on August 19, 2021.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from the reinvestment of dividends, not open-market purchases.
- Executives Involved:
- Dr. H. Barron (Chief Scientific Officer and President, R&D): Acquired 2,516.286 ADSs via the Executive Supplemental Savings Plan and 64 ADSs via the 401(k) plan.
- Mr. J. Ford (SVP & General Counsel): Acquired 62.356 ADSs via the Executive Supplemental Savings Plan.
- Valuation Context: The transactions occurred at a uniform price of $41.81, reflecting the market price on the transaction date.
- Financial Data Limitation: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for performance metrics.